From WES, somatic mutations are identified, and the allele frequency of each mutation is quantified.
Thousands of known disease-causing mutations are identified as well as new disease-linked genes.
Novel mutations are identified by unexpected melting temperature or curve shape changes.
Once those mutations are identified, the hope is that drugs against them can be developed, too.
Alterations in Ret gene are related to several neoplasias: point mutations are identified in medullary thyroid carcinoma (MTC) and multiple endocrine neoplasias 2A and B (MEN2A and B), while translocations and chromosomal inversions cause papillary thyroid carcinoma (PTC).
Such mutations are identified in a number of endocrine disorders, including McCune-Albright syndrome, which is a triad of endocrinopathy, café au lait spots, and polyostotic fibrous dysplasia.
As more patients with PNKP mutations are identified through genetic testing, the clinical spectrum of this disease will likely be further refined.
It is little wonder that many worry that as an increasing number of mutations are identified and tested for, the range of what is considered normal may narrow, with diminished tolerance for those people who lie outside this range.
Thus, DDX41 and other members of the DEAD/H-box family gene mutations are identified functionally relevant as a novel family of mutations with possible implications for prognosis and treatment of myeloid malignancies, which may lead to approaches of therapeutic schedule (Antony-Debre and Steidl, 2015).
In addition, distinct heterozygous SDHB missense DNA mutations are identified in Jurkat and TALL-104 cell lines which are derived from T-ALLs.
However, KRAS mutations are identified in less than half of all colon cancers, and the role of wild-type KRAS in the hypoxic response is less certain.
